Trevogrumab (REGN1033) is a fully human monoclonal antibody that specifically binds and neutralizes myostatin (GDF-8), developed by Regeneron Pharmaceuticals. It is being studied in combination with other agents for sarcopenia (age-related muscle loss) and muscle wasting conditions. Trevogrumab represents the pharmaceutical industry approach to myostatin inhibition, offering high target specificity and extended half-life compared to peptide-based approaches. It is being studied in combination with garetosmab (anti-activin A antibody) in the TOPAZ program for inclusion body myositis.
Category: Muscle Growth / Monoclonal Antibody. Evidence rating: C (early/mixed human evidence).
Clinical status: Phase 2-3 clinical trials. Being studied in TOPAZ program for inclusion body myositis (with garetosmab).
Trevogrumab is an IgG4 monoclonal antibody that binds mature myostatin with high affinity and specificity, preventing it from engaging activin type IIB receptors (ActRIIB) on skeletal muscle cells. By neutralizing circulating myostatin, it removes the negative regulation of muscle growth, allowing…
Research base: 0 registered clinical trials and 1 indexed publication reference Trevogrumab.
Safety considerations: Phase 1 data showed generally well-tolerated profile; Injection site reactions common with SC administration; Potential for immunogenicity (anti-drug antibodies).
Reviewed by the PeptideAtlas Editorial Team.
| Production method | recombinant |
|---|---|
| Anti-doping status | Prohibited in sport (WADA) |
| US regulatory status | Not FDA-approved. Phase 2-3 trials ongoing (Regeneron). |
No. Trevogrumab is only available through Regeneron clinical trials. It is a complex monoclonal antibody that cannot be synthesized by research chemical suppliers.
Trevogrumab is the most specific approach: it targets only myostatin. Follistatin inhibits myostatin plus activins and GDF-11. ACE-031 (soluble ActRIIB) also has broad target engagement. Specificity may mean fewer side effects but potentially less potent muscle growth effects.
Trevogrumab (REGN1033) is a fully human monoclonal antibody that specifically binds and neutralizes myostatin (GDF-8), developed by Regeneron Pharmaceuticals. It is being studied in combination with other agents for sarcopenia (age-related muscle loss) and muscle wasting conditions. Trevogrumab represents the pharmaceutical industry approach to myostatin inhibition, offering high target…
On the PeptideAtlas A–F scale, Trevogrumab is rated C (Early Evidence). Early human evidence, limited trials, or mixed findings
Phase 2-3 clinical trials. Being studied in TOPAZ program for inclusion body myositis (with garetosmab).